https://www.aidsmap.com/news/may-2018/dolutegravir-may-cause-birth-defects-european-medicines-agency-warns
Regulatory agencies in the United States and European Union have warned that women with HIV who can become pregnant should not use the integrase inhibitor...
european medicines agencybirth defectsdolutegravirmaycause
https://www.aidsmap.com/bulletin/conference-news/croi-2020/13-march-2020
We work to change lives by sharing information about HIV & AIDS. We believe independent, clear and accurate information is vital
hiv treatmentcroidolutegravirbasedsafest
https://www.gsk.com/en-gb/media/press-releases/switching-to-a-dolutegravir-regimen-from-a-boosted-protease-inhibitor-regimen-maintained-viral-suppression-and-improved-lipid-fractions/
ViiV Healthcare and NEAT-ID announced results from the NEAT 022 study of more than 400 patients with HIV and high cardiovascular risk
protease inhibitorswitchingdolutegravirregimenboosted
https://www.news-medical.net/news/20220418/Study-identifies-Etravirine-and-Dolutegravir-as-effective-entry-inhibitors-of-wild-type-and-predominant-variants-of-SARS-CoV-2.aspx
Researchers identified drugs inhibiting the entry of SARS-CoV-2.
entry inhibitorsstudyidentifiesetravirinedolutegravir
https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment.
viiv healthcarephase iiilaunchesprogrammeevaluating
https://www.openpr.com/news/4359011/track-dolutegravir-price-trend-historical-and-forecast
Press release - ChemAnalyst - Track Dolutegravir Price Trend Historical and Forecast - published on openPR.com
price trendtrackdolutegravirhistoricalforecast
https://www.aidsmap.com/news/aug-2018/neuropsychiatric-side-effects-lead-only-1-40-drop-dolutegravir-french-study-shows
A large French study of people taking HIV treatment that contained an integrase inhibitor found that approximately one person in forty who started treatment...
side effectsneuropsychiatricleaddrop